Skip to main content

Peer Review reports

From: Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

Original Submission
10 Sep 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
19 Jan 2023 Reviewed Reviewer Report - Lucjan Wyrwicz
21 Jan 2023 Reviewed Reviewer Report - Ruben Dario Kowalyszyn
29 Jan 2023 Reviewed Reviewer Report
8 Feb 2023 Author responded Author comments - Ting Deng
Resubmission - Version 3
8 Feb 2023 Submitted Manuscript version 3
11 Feb 2023 Reviewed Reviewer Report
19 Feb 2023 Reviewed Reviewer Report - Lucjan Wyrwicz
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
20 Feb 2023 Editorially accepted
5 Mar 2023 Article published 10.1186/s12885-023-10661-4

You can find further information about peer review here.

Back to article page